TransCode Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
RNAZ Nasdaq 2830 www.transcodetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - Jan 6th, 2026 6:01 am
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - Dec 22nd, 2025 6:01 am
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - Dec 11th, 2025 6:05 am
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - Nov 17th, 2025 6:01 am
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - Oct 14th, 2025 6:06 am
Sector Update: Health Care Stocks Advance Late Afternoon - Oct 8th, 2025 1:34 pm
Sector Update: Health Care Stocks Advance Wednesday Afternoon - Oct 8th, 2025 11:42 am
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences - Oct 8th, 2025 8:54 am
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - Oct 8th, 2025 6:01 am
Wall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal - Jul 23rd, 2025 7:16 am
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - May 28th, 2025 6:00 am
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - May 8th, 2025 6:05 am
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - May 5th, 2025 3:00 pm
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - May 2nd, 2025 2:10 pm
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - May 1st, 2025 12:30 pm
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer - May 1st, 2025 7:01 am
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug - May 1st, 2025 6:32 am
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - Apr 21st, 2025 2:30 pm
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - Apr 18th, 2025 10:00 am
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 - Mar 27th, 2025 2:37 pm